AKIP1 and cancer: Subgroup analysis according to cancer type indicated that increased AKIP1 expression was closely associated with an unfavorable OS in patients with digestive system cancers (HR = 2.15, 95% CI: 1.44–3.20, P < .001), genitourinary system cancers (HR = 1.79, 95% CI: 1.41–2.28, P < .001), blood system cancers (HR = 1.86, 95% CI: 1.38–2.50, P < .001), head and neck cancers (HR = 1.22, 95% CI: 1.01–1.47, P = .042), NSCLC (HR = 1.76, 95% CI: 1.49–2.06, P < 0.001), and breast cancer (HR = 2.89, 95% CI: 1.10–4.22, P = .022).